Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9584501 | 0.91 | TSHR (0.50) | ALDH1A1MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL568818 | 0.84 | TSHR (0.47) | ALDH1A1MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1396142 | 0.82 | LMNA (0.56) | ALDH1A1MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1583808 | 0.81 | CYP1A2 (0.47) | ALDH1A1MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL6306521 | 0.81 | TSHR (0.44) | ALDH1A1MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL4008417 | 0.79 | MEN1 (0.44) | ALDH1A1MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL158497 | 0.78 | TSHR (0.55) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| Hydrochloric Acid SCHEMBL27776511 | 0.77 | TSHR (0.53) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL17624550 | 0.77 | TSHR (0.44) | ALDH1A1MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL17014920 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3094318-B1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | KANNALIFE SCIENCES INC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | KANNALIFE SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | KANNALIFE SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | KANNALIFE SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | KANNALIFE SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | KANNALIFE SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9611213-B2 | Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy | KANNALIFE SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611213-B2 | Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy | KANNALIFE SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611213-B2 | Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy | KANNALIFE SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-3094318-A2 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | Kannalife, Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160311769-A1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY | KANNALIFE SCIENCES, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311769-A1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY | KANNALIFE SCIENCES, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311769-A1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY | KANNALIFE SCIENCES, INC. | 2016-10-27 | — | — | US | disclosed |
| WO-2015106108-A2 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | KANNALIFE, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106108-A2 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | KANNALIFE, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-5883102-A | Pharmaceutically active compounds | ASTRA PHARMACEUTICALS LIMITED (GB) | 1999-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | TXNRD2, KEAP1, GOT2 | ALDH1A1 195/4885MAPT 647/4885MEN1 3497/4885 |
| US-20160311769-A1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY | EPHX1, DBH, EPHX2 | ALDH1A1 197/4885MAPT 1546/4885MEN1 2010/4885 |
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | TXNRD2, KEAP1, GOT2 | ALDH1A1 195/4885MAPT 647/4885MEN1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.